Why the study?
Diabetes mellitus exacerbates myocardial ischemia/reperfusion injury, but the underlying mechanisms remain unclear.
Does combination treatment with pyridoxamine and empagliflozin improve cardiac recovery and mitigate mitochondrial damage and PANoptosis in diabetic mice with myocardial ischemia/reperfusion injury?
Population
Diabetic mice and cardiomyocytes subjected to hypoxia/reoxygenation or MI/R
Comparison
Combination treatment with pyridoxamine and empagliflozin vs comparator
Design
Preclinical animal and cellular mechanistic study
Key result
Combination therapy with pyridoxamine and empagliflozin in diabetic mice suppressed AGEs accumulation, mitigated mitochondrial damage and PANoptosis, and improved cardiac recovery post-MI/R.
Authors
Loading...
May caution against unchecked AGEs in diabetic reperfusion; leaves open whether targeting them improves clinical MI/RI outcomes.
Does combination treatment with pyridoxamine and empagliflozin improve cardiac recovery and mitigate mitochondrial damage and PANoptosis in diabetic mice with myocardial ischemia/reperfusion injury?
Targeting the AGEs-mitochondrial damage-PANoptosis axis with pyridoxamine and empagliflozin represents a promising strategy to alleviate diabetic myocardial ischemia/reperfusion injury.
Yang et al. (2026) studied Myocardial ischemia/reperfusion injury in diabetes mellitus. Pyridoxamine and empagliflozin was evaluated on Cardiac recovery post-MI/R. Combination therapy with pyridoxamine and empagliflozin in diabetic mice suppressed AGEs accumulation, mitigated mitochondrial damage and PANoptosis, and improved cardiac recovery post-MI/R.